EVIDENCE LIBRARY
Matched ICU Study Found a Small Blood-Pressure Difference Without Improved Major Outcomes
A matched observational study associated remimazolam with less hypotension than propofol in ventilated patients. It did not show better survival, shorter ventilation, or shorter hospital stay.
A matched observational study associated remimazolam with less hypotension than propofol in ventilated patients. It did not show better survival, shorter ventilation, or shorter hospital stay.
What matching produced
Xie and colleagues analyzed 183 matched pairs from one intensive-care setting. The primary measure was change in mean arterial pressure during sedation. Median change was 13 versus 14 mmHg, a statistically significant but numerically small difference.
Hypotension and high-dose norepinephrine use were less common with remimazolam. Major outcomes, including ventilation duration, lengths of stay, and twenty-eight-day mortality, did not differ significantly.
Residual differences remain possible
Propensity matching balances selected recorded characteristics, not all factors guiding treatment. The investigators could not connect real-time dose adjustments with immediate pressure changes through a detailed time-series or dose-response analysis.
The study occurred during the pandemic, included patients with complex interventions, and did not assess delirium. These limitations restrict application to other critical-illness populations and outcomes.
An outcome-specific conclusion
Describe the hemodynamic association separately from survival and recovery. Statistical significance does not determine clinical importance by itself. The paper cannot establish that remimazolam caused an individual patient to survive or that it prevents pressure instability in every mechanically ventilated patient.
Source paper
Original analysis of the supplied journal article, identified as PMC13255365.